These data indicate BCL2A1 is an early response factor in the stressed tumor microenvironment, and targeting BCL2A1 may be a potential therapeutic approach in eradicating peritoneal metastases of ovarian cancer. The gene discussed is BCL2A1; the disease is ovarian cancer.